English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 24 July 2019, 15:00 HKT/SGT
Share:
    

Source: Singapore eDevelopment Ltd
Global BioLife Inc.'s Naturally Modified Sugar Laetose(TM) Unveiled at Harvard Global Health Summit

SINGAPORE, July 24, 2019 - (ACN Newswire) - SGX-listed Singapore eDevelopment Ltd ("SeD", SGX:40V) is pleased to announce the results of clinical trials conducted on Laetose(TM), a low-glycemic, naturally modified sugar, developed by its U.S. biomedical subsidiary Global BioLife Inc. ("Global BioLife").

Clinical trial results show that Laetose is a new sugar product that reduces its negative impact on the body. It is a healthier sweetener that is identical to regular sugar in taste, texture and shelf life, but a naturally modified table sugar which carries 30% fewer calories and a glycemic index score of 53 as compared to a score of 100 in glucose.

Laetose was developed by Mr Daryl L.Thompson, Global BioLife's Director of Scientific Initiatives, who was invited to present the new formula to health ambassadors from around the world at Harvard Medical School's Global Health Catalyst Summit, an annual event that focuses on initiatives to eliminate global health disparities.

"You can think of Laetose as Sugar 2.0. It is more than a low-calorie sugar, but rather a solution to sugar itself in that it was specifically formulated to fight disease," said Mr Thompson. "We've developed a formula that uses sugar the way nature intended. Laetose tastes and performs exactly like sugar as a food ingredient but it is better accepted by the body."

Mr Thompson announced the completion of human trials on Laetose, conducted at one of the foremost laboratories in the world to measure glycemic index, with additional independent testing conducted at Charles River Laboratories showing Laetose halts stimulation of lipopolysaccharide inflammation which leads to Metabolic Endotoxemia, the root of metabolic-driven disease.

Global BioLife has partnered with Quality Candy Company LLC to form a joint venture, Sweet Sense Inc., to produce and market Laetose. Sweet Sense refined the formula at its production facility and created a scalable manufacturing process for Laetose.

"Clinical trials are complete, patents have been filed and the product is ready for full-scale production," said Mr Thompson. Sweet Sense is looking to licence Laetose and is sourcing for companies with the ability to introduce Laetose into multiple food products around the world.

Shareholders and potential investors of SeD are advised to exercise caution when dealing or trading in the securities of SeD. In particular, there is no certainty or assurance that Laetose will be licensed or come close to monetisation. Shareholders and potential investors should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about actions they should take.

About Singapore eDevelopment Ltd
Incorporated on 9 September 2009 and listed on the SGX in July 2010, Singapore eDevelopment Ltd is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg or email: [email protected].

About Global BioLife Inc.
Global BioLife Inc. (GBLI) is a 70%-held direct subsidiary of Global BioMedical Inc., which is a wholly-owned subsidiary of Singapore BioMedical Pte. Ltd., itself a wholly-owned subsidiary of Singapore eDevelopment Ltd, a company listed on the SGX. Remaining shares are held by Global Research and Discovery Group Scientific LLC (GRDGS) at 20% and ASX-listed Holista CollTech Limited at 10%.

GBLI strives to leverage its scientific know-how and intellectual property to provide solutions to problems that have been plaguing the biomedical field for decades. Tapping the scientific expertise of GRDGS and Holista, GBLI pledges a concerted effort in R&D, drug discovery and development for the prevention, inhibition and treatment of neurological, oncology and immuno-related diseases. GBLI is also collaborating with partners to develop second generation, DEET alternative mosquito defense technologies to protect against diseases such as Zika, Dengue, West Nile Virus and Malaria. For more information, please visit: http://www.globalbiolife.com.


Topic: Research and development
Sectors: Daily Finance, Food/Beverage, BioTech, HealthCare, Cosmetics/Spec.Chem
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Singapore eDevelopment Ltd Releated News
June 12, 2019 14:00 HKT/SGT
Global BioLife's new mosquito repellent formula performs well against mosquitos in independent testing
Jan 28, 2019 12:00 HKT/SGT
Singapore eDevelopment subsidiary Global BioLife's 3F Antimicrobial Fragrance shows Efficacy against Tuberculosis
Nov 7, 2018 19:00 HKT/SGT
Singapore eDevelopment Subsidiary, Global BioLife, Proudly Announces Presentation of Parkinson's Research at Neuroscience 2018
June 18, 2018 19:00 HKT/SGT
Singapore eDevelopment Announces Corporate and Business Update
May 31, 2018 18:00 HKT/SGT
Singapore Exchange-Listed Singapore eDevelopment Limited's U.S. Biomedical Subsidiary Global BioLife, Inc. Develops Low Glycemic Modified Sugar
More news >>
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575